Abstract Purpose: [ 11 C]T-773 is a new radioligand for positron emission tomography (PET) targeting the phosphodiesterase 10A enzyme (PDE10A). PDE10A is highly expressed in the striatum by medium spiny neurons, and it has been demonstrated to be involved in the regulation of striatal signaling through the reduction of medium spiny neuronal sensitivity towards glutamatergic excitation. PDE10A is associated with Parkinson's disease and different neuropsychiatric disorders such as Huntington's disease, obsessive-compulsive disorders (OCD) and schizophrenia. Studies have indicated that the inhibition of PDE10A may represent a novel therapeutic approach to the treatment of the aforementioned diseases characterized by the reduced activity of medium spiny neurons. An appropriate PET radioligand for PDE10A would help to facilitate drug development and drug evaluation. 
Introduction
P hosphodiesterases (PDEs) are a group of enzymes which regulate the degradation of cyclic nucleotides, including cAMP and cGMP [1] . As these cyclic nucleotides play an eminent role in neuronal cell function, and, consequently, the regulation of their intracellular degradation, they are of key importance for neuronal function under physiological conditions.
There are at least a dozen PDE families with involvement in various biochemical processes. Several of the PDEs have been identified to have clear contributions in various neurological or psychiatric diseases. In particular, phosphodiesterase 10A enzyme (PDE10A) may play a role in those CNS disorders that involve striatal neurons in the brain, including Huntington's disease (HD) [2] . PDE10A is highly expressed in the striatal medium spiny neurons, which are vulnerable and degenerated in HD, and regulates both cAMP and cGMP signaling cascades and the inhibition of PDE10A results in a significant increase in CREB phosphorylation in the striatum. In line with these observations, several studies have indicated that PDE10A inhibition may be a novel therapeutic approach to the treatment of the aforementioned diseases characterized by a reduced activity of medium spiny neurons [3] .
Consequently, the exploration of the normal distribution of PDE10A in the human brain, with special regard to the striatum, is of high interest in HD research. Furthermore, the development of PDE10A-selective positron emission tomography (PET) radioligands is of high importance as these molecular biomarkers may serve as molecular imaging biomarkers in the development of therapeutic drugs, serve as markers to establish the diagnosis of HD, and allow monitoring of the therapeutic effect of drugs in HD patients.
Recently, several attempts have been made to identify an optimal PET radioligand for PDE10A, such as [ 11 [4] [5] [6] [7] [8] [9] [10] . However, due to various reasons (low binding potential, short retention time in striatum, need for arterial input function, etc.), none of these radioligands have proven to be optimal for small animal molecular imaging studies, and therefore further radioligand developments are still ongoing.
Our aim was to test a novel radioligand, [ 11 C]T-773, with high affinity for PDE10A [11] , in a small animal disease model of HD (PDE10A C57 mutant), the PDE10A knockout mouse model, using a high-resolution-high-sensitivity preclinical hybrid imaging system, the Mediso nanoScan PET/ magnetic resonance imaging (MRI) and nanoScan PET/Xray computed tomography (CT) scanners [12, 13] .
Materials and Methods

Animals
Six homozygous (HOM) and six heterozygous (HET) male B6.D1-Pde10aGtm1Pfi9/J [14] were imaged together with six male wildtype (WILD) control C57BL/6 J mice at 4 months of age from Charles River Laboratories (Sulzfeld, Germany). The animals were housed in groups, with cages ventilated individually (thermoregulated ∼22°C, humidity-controlled), under a 12-h/12-h light/dark cycle with access to food and water ad libitum.
All animal experiments were conducted according to the appropriate Swedish regulations with the approval of the Animal Research Ethics Committee of the Swedish Animal Welfare Agency (Northern Stockholm Region) and were performed according to the guidelines of Karolinska Institutet regarding working with experimental animals (Dnr.: N210/10, N40/11).
Radiochemistry
[ 11 C]T-773 was labelled by an O-methylation reaction as described elsewhere [15] . Briefly, the desmethyl precursor was reacted with [ 11 C]MeOTf in acetone at room temperature, using 0.5 M aq. NaOH as base. The labelled compound was then purified by reverse-phase chromatography using Supelco Ascentis RP-amide column (250×10 mm) and MeCN/0.1 % aq. TEA as eluent, followed by SPE procedure using Water Oasis 1 cc cartridge and formulated in 10 % EtOH/PBS mixture. Radiochemical purity was 995 %, and specific activity at time of injection was 250-1350 GBq/μmol. The mean administered mass was 0.015± 0.006 μg.
In vivo Imaging with PET
The mice were anaesthetized by inhalation of isoflurane (4-5 % isoflurane in 100 % oxygen). After induction of anaesthesia, the isoflurane concentration was lowered to 1.5-2 % (50/50 air/oxygen mixture at a flow rate of 1 l/min) and a cannula was inserted into the tail vein. A bolus injection of [ 11 C]T-773 (max. 0.3 ml) was given the same time as the initiation of the PET measurement; the average amount of injected radioactivity was 12.8±2.6 MBq (n=18) and it was followed by a 0.1-ml saline flush. The average weight of the animals was 28.2±3.3 g (n=18), while the average injected mass was 0.013±0.005 μg (n=18).
Two animals were examined at the same time for 63 min in identical PET modules of nanoScan® PET/MRI and nanoScan® PET/ CT pre-clinical small animal imaging systems [12, 13] . The animals were positioned so that the brain was at the central part of the field of view. The data were acquired in list mode and were reconstructed into 25 timeframes (4×10, 4×20, 4×60, 7×180, and 6×360 s) with a fully 3-dimensional maximum likelihood expectation maximization (MLEM) reconstruction algorithm (20 iterations).
Data Analysis
In the analysis software PMOD, the reconstructed dynamic PET measurements were manually aligned with PMOD's mice brain template using summed images of different timeframes (1-8 and 8-63 min) (PMOD 3.3 Zurich, Switzerland). To acquire the decaycorrected time-activity curves (TAC) for the striatum (caudate/ putamen), cortex and cerebellum, a slightly adjusted version of PMOD's template was used. Regional brain uptake values were expressed as percent standardized uptake value (%SUV) and were calculated for the 15-63 min time period, as can be seen in Fig. 1 .
Non-displaceable binding potential (BP ND ) was estimated by PMOD using simplified reference tissue modeling (SRTM) [16] with cerebellum as the reference region. Statistical analysis was conducted using one-way ANOVAs (with Bonferroni's post-hoc tests) on %SUV and BP ND values.
Results
Images with good signal-to-noise ratios were obtained. Highest brain uptake was seen for striatum of the WT mice, while lowest in the HOM mice. Approximately, the same level of high uptake was observed in the Harderian glands in all mice breeds, indicating no difference in nonspecific uptake. [ 11 C]T-773 showed acceptable uptake in the striatum in WILD mice, moderate uptake in HET mice and low uptake in HOM mice (Fig. 2) .
The TACs showed increasing radioligand accumulation in the striatum with peak equilibrium of [
11 C]T-773 at ∼20 min in wild-type animals (Fig. 3) . Wash-out from other brain regions was faster compared to wild-type striatum. Low standard deviations were seen within groups, indicating good reliability of the ligand.
The striatum binding ratio in HOM mice indicates that the cerebellum TAC was somewhat higher compared to the striatum. The small increase in the cerebellum could be a "spillover" effect from the tissue surrounding the cerebellum. Since brain uptake of the radioligand is much lower than in tissue uptake outside of the brain, there is a slight partial volume effect on the cerebellum and cortex, but not on the striatum.
Regarding the regional %SUV values, differences with high statistical significance was found between the various animal groups with only six animals in striatal and cortical regions (Fig. 4) 
Discussion
It has been shown that high levels of PDE10A enzyme levels are present in medium spiny neurons of the caudate nucleus, nucleus accumbens and olfactory tubercle in rodents using a monoclonal antibody [17] . Since small regions in the mouse brain (such as the nucleus accumbens and olfactory tubercle) are subject to high signal to noise ratios, our main focus was to assess the uptake of a novel PET radioligand only in the striatum of mice expressing different levels of PDE10A.
Molecular imaging of the PDE10A system in rodents and nonhuman primates has recently been performed with various PET radioligands, with varying success. PET imaging with [ 11 C]papaverin yielded disappointing results Fig. 1 Formula of the calculation of the percent of standardized uptake value (%SUV). as hardly any residual radioactivity or discernible specific binding was retained in striatum at times after 10 min [4] . Imaging results with [ 11 C]MP-10 in the pig and baboon brain were encouraging when a two-tissue compartment model was used, but this approach requires the measurement of an arterial input function [5] and, consequently, it can be a limiting factor in both rodent studies and scanning of n e u r o l o g i c a l p a t i e n t s . [6, 18] . Whereas [ 1 8 F]JNJ42259152 appeared to be superior to [ 18 F]JNJ41510417 due to faster kinetics, quantification of the images obtained with both radioligands requires the measurement of an arterial input function. Furthermore, when the simplified reference tissue model approach is applied to the data obtained with [ 18 F]JNJ42259152 (using the cerebellum as reference region), the presence of a polar radiometabolite resulted in an underestimation of the striatal BP ND in the rat brain [18] . Consequently, no optimal PET radioligand for the visualization of the PDE10A enzyme has been available.
Based on our present experiments in PDE10A knockout mice, [ 11 C]T-773 is a promising PET radioligand for in vivo visualization and quantification of PDE10A in the rodent brain, with a focus on the striatum, using SRTM for the quantitative analysis of the imaging data. [ 11 C]T-773 showed high specific binding to PDE10A with significant accumulation of the radioligand in the striatum over time, whereas there was a clear washout from the other brain regions examined (i.e., cerebellum and cortex). Based on %SUV values (15-63 min), the uptake of radioligand in the striatum of HOM mice was 44 % lower compared to WILD mice and 25% lower in HET mice. The quantitative analysis with SRTM also showed a significant decrease in striatal BP ND in HET and HOM mice compared to WILD. In nonhuman primate experiments, it has been shown that 
radiometabolites of [
11 C]T-773 are unlikely to enter the brain, and while these results were acquired in venous blood samples, it is at least an indication for the absence of brain penetrating radiometabolites [11] . In mice, further studies are required to expand our knowledge on metabolites of [ 11 C]T-773.
The significant reduction of binding in the striatum in PDE10A knockout mice confirms that [
11 C]T-773 binds selectively to PDE10A, while the clear regional distribution of uptake strengthens the suitability of [
11 C]T-773 as a radioligand for imaging PDE10A.
